Browse studies
Find your next paid study
3 recruiting studies matching your filters
ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC)
Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical tr…
HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more
University of California, San FranciscoNCT06774027
Phase 2
Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal gro…
Breast CancerBreast NeoplasmsBreast Cancers
Baylor Research InstituteNCT06517212
Phase 2
Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be …
Metastatic Triple Negative Breast Cancers
Yale UniversityNCT07458113